The analgesic potential of clostridial neurotoxin derivatives
- 1 November 2004
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 13 (11), 1437-1443
- https://doi.org/10.1517/13543784.13.11.1437
Abstract
Botulinum neurotoxins are the most potent acute lethal toxins known, and yet for the last two decades they, and in particular serotype A, have found increasing use in the clinical treatment of diseases or conditions involving neuromuscular or autonomic neuronal transmission. The neurotoxins work by inhibiting the release of acetylcholine from peripheral cholinergic nerve terminals. More recently, the effects on non-cholinergic pathways have been identified, and this has led to an increase in the diseases and syndromes for which botulinum neurotoxins have been found to have clinical utility. In particular, botulinum neurotoxins have been demonstrated to potentially benefit a range of chronic pain syndromes. With the description in the last decade of the biochemical basis of neurotoxin action and the tertiary structure of the toxin molecule, the possibility of designing novel agents utilising selected aspects of toxin function has arisen. This possibility has been pursued in the context of pain relief with the description of a novel hybrid protein derived from botulinum neurotoxin type A, LH(N)/A-ECL, able to selectively target nociceptive afferent neurons and inhibit the release of neurotransmitters involved in pain transmission. This novel derivative of botulinum neurotoxin type A demonstrates prolonged analgesic activity in vivo. This review will consider the evidence for the analgesic properties of the botulinum neurotoxins and their suitability as the basis for novel therapeutic proteins. The general concept of deriving novel therapeutic molecules from the neurotoxins will also be considered.Keywords
This publication has 26 references indexed in Scilit:
- Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor ActivityJournal of Biological Chemistry, 2004
- Botox: beyond wrinklesClinics in Dermatology, 2004
- Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effectsExpert Opinion on Investigational Drugs, 2001
- The Role of the Synaptic Protein SNAP-25 in the Potency of Botulinum Neurotoxin Type AJournal of Biological Chemistry, 2001
- Inhibition of Vesicular Secretion in Both Neuronal and Nonneuronal Cells by a Retargeted Endopeptidase Derivative of Clostridium botulinum Neurotoxin Type AInfection and Immunity, 2000
- A Conjugate Composed of Nerve Growth Factor Coupled to a Non-toxic Derivative ofClostridium botulinumNeurotoxin Type A can Inhibit Neurotransmitter Releasein VitroGrowth Factors, 2000
- SNAP receptors implicated in vesicle targeting and fusionNature, 1993
- A 50‐kDa fragment from the NH2‐terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesiclesEuropean Journal of Biochemistry, 1987
- Evidence for glycoconjugate in nociceptive primary sensory neurons and its origin from the golgi complexBrain Research, 1986
- Molecular Pharmacology of Botulinum Toxin and Tetanus ToxinAnnual Review of Pharmacology and Toxicology, 1986